Overexpression of BMI-1 correlates with drug resistance in B-cell lymphoma cells through the stabilization of survivin expression

Cancer Science

Volumn 103, Issue 1, 2012, Pages 34-41

  Bhattacharyya, Joyeeta ^a   Mihara, Keichiro ^a   Ohtsubo, Motoaki ^a   Yasunaga, Shin'ichiro ^a   Takei, Yoshifumi ^b   Yanagihara, Kazuyoshi ^c   Sakai, Akira ^a   Hoshi, Masaharu ^a   Takihara, Yoshihiro ^a   Kimura, Akiro ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c YASUDA WOMEN'S UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BMI1 PROTEIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; OXALIPLATIN; PREDNISOLONE; RITUXIMAB; SURVIVIN; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; HUMAN; HUMAN CELL; LYMPHOMA CELL; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CAMPTOTHECIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LYMPHOMA, B-CELL; NUCLEAR PROTEINS; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 84855513342     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02121.x     Document Type: Article

References (28)

1. Raaphorst FM. Deregulated expression of Polycomb-group oncogenes in human malignant lymphomas and epithelial tumors. Hum Mol Genet 2005; 14: R93-100.
2. Jacobs JJ, van Lohuizen M. Polycomb repression: from cellular memory to cellular proliferation and cancer. Biochim Biophys Acta 2002; 1602: 151-61.
3. Haupt Y, Alexander WS, Barri G et al. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell 1991; 65: 753-63.
4. Park IK, Morrison SJ, Clarke MF. Bmi1, stem cells, and senescence regulation. J Clin Invest 2004; 113: 175-9.
5. Chowdhury M, Mihara K, Yasunaga S et al. Expression of Polycomb-group (PcG) protein BMI-1 predicts prognosis in patients with acute myeloid leukemia. Leukemia 2007; 21: 1116-22.
6. Bhattacharyya J, Mihara K, Yasunaga S et al. BMI-1 expression is enhanced through transcriptional and posttranscriptional regulation during the progression of chronic myeloid leukemia. Ann Hematol 2009; 88: 333-40.
7. Mihara K, Chowdhury M, Nakaju N et al. Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis. Blood 2006; 107: 305-8.
8. Song LB, Li J, Liao WT et al. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest 2009; 119: 3626-36.
9. Mohty M, Yong AS, Szydlo RM et al. The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood 2007; 110: 380-3.
10. Yamamoto H, Ngan CY, Monden M. Cancer cells survive with survivin. Cancer Sci 2008; 99: 1709-14.
11. Altieri DC. Survivin in apoptosis control and cell cycle regulation in cancer. Prog Cell Cycle Res 2003; 5: 447-52.
12. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3: 46-54.
13. Hayashi N, Asano K, Suzuki H et al. Adenoviral infection of survivin antisense sensitizes prostate cancer cells to etoposide in vivo. Prostate 2005; 65: 10-19.
14. Ansell SM, Arendt BK, Grote DM et al. Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia 2004; 18: 616-23.
15. Blanc-Brude OP, Mesri M, Wall NR et al. Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res 2003; 9: 2683-92.
16. Zaffaroni N, Daidone MG. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat 2002; 5: 65-72.
17. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83: 993-1000.
18. Jacobs JJ, Kieboom K, Marino S et al. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999; 397: 164-8.
19. Smith KS, Chanda SK, Lingbeek M et al. Bmi-1 regulation of INK4A-ARF is a downstream requirement for transformation of hematopoietic progenitors by E2a-Pbx1. Mol Cell 2003; 12: 393-400.
20. Lin J, Hsiao PW, Chiu TH, Chao JI. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells. Biochem Pharmacol 2005; 70: 658-67.
21. Fujie Y, Yamamoto H, Ngan CY et al. Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells. Jpn J Clin Oncol 2005; 35: 453-63.
22. Zhao J, Tenev T, Martins LM et al. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci 2000; 113: 4363-71.
23. Coiffier B. Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma. Semin Oncol 2004; 31: 7-11.
24. Fortugno P, Beltrami E, Plescia J et al. Regulation of survivin function by Hsp90. Proc Natl Acad Sci USA 2003; 100: 13791-6.
25. Sato S, Fujita N, Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 2000; 97: 10832-7.
26. Lee K, Adhikary G, Balasubramanian S et al. Expression of Bmi-1 in epidermis enhances cell survival by altering cell cycle regulatory protein expression and inhibiting apoptosis. J Invest Dermatol 2008; 128: 9-17.
27. Song W, Tao K, Li H et al. Bmi-1 is related to proliferation, survival and poor prognosis in pancreatic cancer. Cancer Sci 2011; 101: 1754-60.
28. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-21.